For example, ripretinib targets KIT, PDGFRα/β, kinase insert domain receptor (KDR), and colony‐stimulating factor 1 receptor (CSF1R alias C‐FMS) and has been developed to overcome the TKI resistance occurring in GIST patients. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.